Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.

摘要: Abstract Objectives Analysis of the targetable driver mutations is now recommended in all patients with advanced lung adenocarcinoma. Molecular-based methods are usually adopted, however, along implementation highly sensitive and/or mutation-specific antibodies, immunohistochemistry (IHC) has been considered an alternative method for identifying adenocarcinomas. Materials and A total 205 adenocarcinomas were examined EGFR ALK ROS1 rearrangements using real-time PCR, fluorescence situ hybridization (FISH) IHC parallel. The performance different commercially available antibody clones toward was evaluated. association between these clinicopathological characteristics also analyzed. Results In cases we studied, 58.5% found to harbor mutations, 6.3% 1.0% rearrangements. Compared molecular-based methods, showed excellent specificity but sensitivity suboptimal, while demonstrated high specificity. No significant difference regarding observed, except that clone SP125 a higher than 43B2 detection p.L858R EGFR. Conclusion circumstances such as poor quality nucleic acids or low content tumor cells, antibodies could be used method. Patients negative subjected further analysis on methods. Herein, proposed adenocarcinoma testing algorithm application therapeutic diagnosis.